The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.
Tumor-Associated Macrophages: From Mechanisms to Therapy
Open accessAbstract
The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy. Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression. Clinical studies and experimental mouse models indicate that these macrophages generally play a protumoral role. In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation. During monocytes and/or metastasis, macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth. Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy. Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM re-education, and TAM depletion [88, 96, 101, 102].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“Many therapy strategies have attempted to alter the polarization of macrophages’ “re-programming” or prevent monocyte tumor infiltration (Noy and Pollard, 2014).”
From Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review (2021) · cites this paper as Noy and Pollard, 2014
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [167]
In the citing paper
“The production of colony stimulating factor 1 (CSF-1; also known as macrophage colony stimulating factor) by BCCs, has been reported to stimulate the recruitment of macrophages to primary breast tumors, leading to the secretion by tumor-associated macrophages (TAMs) of epidermal growth factor, which binds to its cognate receptor on BCCs to stimulate invasion and metastasis [36–38].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Forget, M. A., Voorhees, J. L., Cole, S. L., Dakhlallah, D. A., Patterson, I. L., Gross, A. C., Moldovan, L., Mo, X. M., Evans, R., Marsh, C. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098623 · Cited by 79 · cited 2×
“Interestingly, CSF1 upregulates TIE2 on TAMs (Forget et al., 2014) indicating a link between CSF1, TIE2 macrophages, and the induction of the angiogenic switch.”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…the ways in which the microenvironmental support to tumors is the acquisition of a vasculature that provides oxygenation, as well as the nutrition and waste disposal required for growth above a certain size in a process often referred to as the ‘‘angiogenic switch’’ (Hanahan and Weinberg, 2011).”
BackgroundCoussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · cited 1×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 4×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundInfluentialMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 3×
“…SPARC) that increases tumor cell-ECM interaction and thus migration (Sangaletti et al., 2008), Cathepsin proteases that remodel the matrix and release sequestered growth factors (Laoui et al., 2011; Quail and Joyce, 2013) and TGF-b that promotes EMT of the invading tumor cells (Bonde et al., 2012).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 1×
“TheseM-MDSCs have greater immunosuppressive potency than the granulocytic ones and are further defined as F4/80+ a marker also found on inflammatory monocytes (Gabrilovich and Nagaraj, 2009; Gabrilovich et al., 2012).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 2×
“References to these polarizing agents can be found in (De Palma and Lewis, 2013; Sica and Mantovani, 2012). above strongly support targeting the destruction or redifferentiation of macrophages as an important part of combinatorial therapies in human cancer patients.”
BackgroundAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“…the activated macrophages responding to IFN-g, TNF-a, and Toll-like receptor 4 (TLR4) activation capable of killing pathogens through mechanisms such as iNOS, and (2) alternatively activated macrophages responding to IL-4 and IL-13 involved in antiparasitic immunity and in asthma (Gordon, 2003).”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,338 · cited 11×
“Furthermore, in most large-scale transcriptome analysis, macrophages have a mixed phenotype expressing both M1 and M2 markers (Qian and Pollard, 2010).”
BackgroundInfluentialSelf-citation
Flagged first, then by citations
2 of the 136 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,010
Quaranta, V., Rainer, C., Nielsen, S. R., Raymant, M., Ahmed, M. S., Engle, D. D., Taylor, A., Murray, T., Campbell, F., Palmer, D. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3876 · Cited by 171
Hao, J., Yan, F., Zhang, Y., Triplett, A., Zhang, Y., Schultz, D. A., Sun, Y., Zeng, J., Silverstein, K. A. T., Zheng, Q., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2465 · Cited by 171
Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence
Chigbu, D. I., Loonawat, R., Sehgal, M., Patel, D., & Jain, P. (2019) · Cells · doi:10.3390/cells8040376 · Cited by 183
Rong, L., Zhang, Y., Li, W., Su, Z., Fadhil, J. I., & Zhang, C. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119515 · Cited by 167
The Notch signaling pathway: a potential target for cancer immunotherapy
Li, X., Yan, X., Wang, Y., Kaur, B., Han, H., & Yu, J. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01439-z · Cited by 177
Ban, Y., Mai, J., Li, X., Mitchell-Flack, M., Zhang, T., Zhang, L., Chouchane, L., Mauro Ferrari, B., Shen, H., & Ma, X. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2913 · Cited by 168
Rakaee, M., Busund, L., Jamaly, S., Paulsen, E., Richardsen, E., Andersen, S., Al-Saad, S., Bremnes, R., Donnem, T., & Kilvaer, T. (2019) · Neoplasia · doi:10.1016/j.neo.2019.01.005 · Cited by 133
Li, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01636-x · Cited by 172
Lactic acid in macrophage polarization: The significant role in inflammation and cancer
Zhou, H., Yan, X.-Y., Yu, W., Liang, X., Du, X., Liu, Z., Long, J., Zhao, G., & Liu, H.-B. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1955876 · Cited by 172
Macrophage targeting: opening new possibilities for cancer immunotherapy
Cassetta, L., & Kitamura, T. (2018) · Immunology · doi:10.1111/imm.12976 · Cited by 168
Liu, M., Luo, F., Ding, C., Albeituni, S., Hu, X., Ma, Y., Cai, Y., McNally, L. R., Sanders, M. A., Jain, D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501158 · Cited by 174
Dual role of inflammatory mediators in cancer
Shrihari, T. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.721 · Cited by 170
Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization
Tan, B., Shi, X., Zhang, J., Qin, J., Zhang, N., Ren, H., Qian, M., Siwko, S. K., Carmon, K. S., Liu, Q., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0152 · Cited by 166
Liu, J., Bai, Y., Li, Y., Li, X., & Luo, K. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105301 · Cited by 170
Feng, Q., Chang, W., Mao, Y., He, G., Zheng, P., Tang, W., Wei, Y., Ren, L., Zhu, D., Ji, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2076 · Cited by 152
Re-Education of Macrophages as a Therapeutic Strategy in Cancer
Kowal, J., Kornete, M., & Joyce, J. A. (2019) · Immunotherapy · doi:10.2217/imt-2018-0156 · Cited by 161
Davis, R. J., Waes, C. V., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 167
Zhang, X., Chen, L., Dang, W., Cao, M., Xiao, J., Lv, S., Jiang, W.-J., Yao, X.-H., Lu, H.-M., Miao, J., et al. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0345-3 · Cited by 161
Rational Design of Biomaterials to Potentiate Cancer Thermal Therapy
Zhu, Y., Li, Q., Wang, C., Hao, Y., Yang, N., Chen, M., Ji, J., Feng, L., & Liu, Z. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00822 · Cited by 163
The cGAS-STING Pathway: A Promising Immunotherapy Target
Ou, L., Zhang, A., Cheng, Y., & Chen, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.795048 · Cited by 166
The cancer matrisome: From comprehensive characterization to biomarker discovery
Socovich, A. M., & Naba, A. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.06.005 · Cited by 164
Im, J. H., Buzzelli, J. N., Jones, K. I., Franchini, F., Gordon-Weeks, A. N., Markelc, B., Chen, J., Kim, J., Cao, Y., & Muschel, R. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17914-x · Cited by 163
Yang, Y., Li, L., Xu, C., Wang, Y., Wang, Z., Chen, M., Zhou, J., Pan, J., Yang, C., Li, X., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320777 · Cited by 162
Targeting tumor-associated macrophages as an antitumor strategy
Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 162
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska, J. G., Shen, J., & Larionova, I. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01232-z · Cited by 187
“TAMs can secrete large amounts of the immunosuppressive cytokine IL-10, which prevents the tumor cell-killing activity of CD8 + T cells, Th1 cells, and NK cells and activates Treg recruitment [142, 144, 145].”
InfluentialNapolitano, A., Pellegrini, L., Dey, A., LARSON, D. L., Tanji, M., Flores, E. G., Kendrick, B., Lapid, D. J., Powers, A. A., Kanodia, S., et al. (2015) · Oncogene · doi:10.1038/onc.2015.243 · Cited by 161
Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma
Kim, W., Khan, S. K., Liu, Y., Xu, R., Park, O., He, Y., Cha, B., Gao, B., & Yang, Y. (2017) · Gut · doi:10.1136/gutjnl-2017-314061 · Cited by 163
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
Zeng, D., Ye, Z., Wu, J., Zhou, R., Fan, X., Wang, G., Huang, Y., Wu, J., Sun, H., Wang, M., et al. (2020) · Theranostics · doi:10.7150/thno.46176 · Cited by 157
Wang, Y.-C., Wang, X., Yu, J., Ma, F., Li, Z., Zhou, Y., Zeng, S., Ma, X., Li, Y.-R., Neal, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23164-2 · Cited by 161
Mathematical models of tumor cell proliferation: A review of the literature
Jarrett, A. M., Lima, E. A. B. F., Hormuth, D. A., McKenna, M. T., Feng, X., Ekrut, D. A., Resende, A. C. M., Brock, A., & Yankeelov, T. E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527689 · Cited by 168
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Giannone, G., Ghisoni, E., Genta, S., Scotto, G., Tuninetti, V., Turinetto, M., & Valabrega, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124414 · Cited by 159
Sui, S., An, X., Xu, C., Li, Z., Hua, Y., Huang, G., Sui, S., Qian, L., Sui, Y.-X., Xiong, Y., et al. (2020) · Theranostics · doi:10.7150/thno.49451 · Cited by 157
Heparanase and the hallmarks of cancer
Jayatilleke, K. M., & Hulett, M. D. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02624-1 · Cited by 167
Sang, W., Xie, L., Wang, G., Li, J., Zhang, Z., Li, B., Guo, S., Deng, C., & Dai, Y. (2020) · Advanced Science · doi:10.1002/advs.202003338 · Cited by 160
Hu, G., Su, Y., Kang, B. H., Fan, Z., Dong, T., Brown, D. R., Cheah, J. H., Wittrup, K. D., & Chen, J. (2021) · Nature Communications · doi:10.1038/s41467-021-21066-x · Cited by 162
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment
García, C. J. G., Huang, Y., Fuentes, N. R., Turner, M. C., Monberg, M. E., Lin, D., Nguyen, N. D., Fujimoto, T. N., Zhao, J., Lee, J. J., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.02.024 · Cited by 167
A review of microfluidic approaches for investigating cancer extravasation during metastasis
Ma, Y.-H. V., Middleton, K., You, L., & Sun, Y. (2018) · Microsystems & Nanoengineering · doi:10.1038/micronano.2017.104 · Cited by 154
Intertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 160
Myeloid cells in hepatocellular carcinoma
Wan, S., Kuo, N., Kryczek, I., Zou, W., & Welling, T. H. (2015) · Hepatology · doi:10.1002/hep.27867 · Cited by 161
Deng, C., Zhang, Q., Jia, M., Zhao, J., Sun, X., Gong, T., & Zhang, Z. (2019) · Advanced Science · doi:10.1002/advs.201801868 · Cited by 156
Madsen, D. H., Jürgensen, H. J., Siersbæk, M. S., Kuczek, D. E., Cloud, L. G., Liu, S., Behrendt, N., Grøntved, L., Weigert, R., & Bugge, T. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.12.011 · Cited by 157
Bao, X., Shi, R., Zhao, T., Wang, Y., Anastasov, N., Rosemann, M., & Fang, W. J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02669-7 · Cited by 157
Chang, Y. S., Jalgaonkar, S. P., Middleton, J. D., & Hai, T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700455114 · Cited by 157
LAMPs: Shedding light on cancer biology
Alessandrini, F., Pezzè, L., & Ciribilli, Y. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.013 · Cited by 156
Nanostructured particles assembled from natural building blocks for advanced therapies
Ju, Y., Liao, H., Richardson, J. J., Guo, J., & Caruso, F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00343g · Cited by 157
Akalu, Y. T., Rothlin, C. V., & Ghosh, S. (2017) · Immunological Reviews · doi:10.1111/imr.12522 · Cited by 158
Belgiovine, C., Bello, E., Liguori, M., Craparotta, I., Mannarino, L., Paracchini, L., Beltrame, L., Marchini, S., Galmarini, C. M., Mantovani, A., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.205 · Cited by 156
Hashemi, M., Mirdamadi, M. S. A., Talebi, Y., Khaniabad, N., Banaei, G., Daneii, P., Gholami, S., Ghorbani, A., Tavakolpournegari, A., Farsani, Z. M., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106568 · Cited by 153
Zhan, H., Zhou, B., Cheng, Y., Xu, J., Wang, L., Zhang, G., & Hu, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.041 · Cited by 155
The Role of Stroma in Tumor Development
Werb, Z., & Lu, P. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000127 · Cited by 159
The Diverse Roles of Heme Oxygenase-1 in Tumor Progression
Hoang, K. N. L., Anstee, J. E., & Arnold, J. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658315 · Cited by 152
Zheng, Y., Han, Y., Sun, Q., & Li, Z. (2022) · Exploration · doi:10.1002/exp.20210166 · Cited by 151
Fang, D. D., Tang, Q., Kong, Y., Wang, Q., Gu, J., Fang, X., Zou, P., Rong, T., Wang, J., Yang, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0750-6 · Cited by 151
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 154
Ponzoni, M., Pastorino, F., Paolo, D. D., Perri, P., & Brignole, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071953 · Cited by 158
Yang, Y., Sun, M., Yao, W., Wang, F., Li, X., Wang, W., Li, J., Gao, Z., Qiu, L., You, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000317 · Cited by 156
Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment
Lahmar, Q., Keirsse, J., Laoui, D., Movahedi, K., Overmeire, E. V., & Ginderachter, J. A. V. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.009 · Cited by 161
Immune Response Regulation in the Tumor Microenvironment by Hypoxia
Labiano, S., Palazón, A., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.009 · Cited by 155
Kitamura, T., Doughty-Shenton, D., Cassetta, L., Fragkogianni, S., Brownlie, D., Kato, Y., Carragher, N. O., & Pollard, J. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.02004 · Cited by 152
Self-citationMagrone, T., Magrone, M., Russo, M. A., & Jirillo, E. (2019) · Antioxidants · doi:10.3390/antiox9010035 · Cited by 162
Kuo, C., Chou, H.-Y., Chiu, Y.-C., Cheng, A. N., Fan, C., Chang, Y., Chen, C., Jiang, S. S., Chen, N., & Lee, A. Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.019 · Cited by 152
Monocyte-endothelial cell interactions in vascular and tissue remodeling
Medrano-Bosch, M., Simón-Codina, B., Jiménez, W., Edelman, E. R., & Melgar‐Lesmes, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196033 · Cited by 168
The interplay of effector and regulatory T cells in cancer
Roychoudhuri, R., Eil, R. L., & Restifo, N. P. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.003 · Cited by 154
Niu, Y., Zhu, J., Li, Y., Shi, H., Gong, Y., Li, R., Huo, Q., Ma, T., & Liu, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.012 · Cited by 149
Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential
Smyth, P., Sasiwachirangkul, J., Williams, R. D., & Scott, C. J. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101106 · Cited by 155
Repenko, T., Rix, A., Ludwanowski, S., Go, D., Kiessling, F. M., Lederle, W., & Kuehne, A. J. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00545-0 · Cited by 158
Interleukin-34, a comprehensive review
Baghdadi, M., Umeyama, Y., Hama, N., Kobayashi, T., Han, N., Wada, H., & Seino, K.-I. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr1117-457r · Cited by 148
Lee, C.-C., Lin, J.-C., Hwang, W., Kuo, Y., Chen, H.-K., Tai, S., Lin, C., & Yang, M. (2018) · Nature Communications · doi:10.1038/s41467-018-06268-0 · Cited by 149
Role of cystathionine β-synthase in human breast Cancer
Sen, S., Kawahara, B., Gupta, D., Tsai, R., Khachatryan, M., Roy‐Chowdhuri, S., Bose, S., Yoon, A. J., Faull, K. F., Farias‐Eisner, R., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.024 · Cited by 149
Lopci, E., Toschi, L., Grizzi, F., Rahal, D., Olivari, L., Castino, G. F., Marchetti, S., Cortese, N., Qehajaj, D., Pistillo, D., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3425-2 · Cited by 145
The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression
Zhong, X., Chen, B., & Yang, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000486816 · Cited by 148
Frank, A.-C., Ebersberger, S., Fink, A. F., Lampe, S., Weigert, A., Schmid, T., Ebersberger, I., Syed, S. N., & Brüne, B. (2019) · Nature Communications · doi:10.1038/s41467-019-08989-2 · Cited by 149
Cysteine Cathepsins in Tumor-Associated Immune Cells
Jakoš, T., Pišlar, A. H., Jewett, A., & Kos, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02037 · Cited by 145
Hou, L., Gong, X., Yang, J., Zhang, H., Yang, W., & Chen, X. S. (2022) · Advanced Materials · doi:10.1002/adma.202200389 · Cited by 148
Hollmén, M., Roudnicky, F., Karaman, S., & Detmar, M. J. (2015) · Scientific Reports · doi:10.1038/srep09188 · Cited by 153
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E. K., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 148
Ramachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G. J., Bath, N. M., Tipping, A. J., Melchiori, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0762-2 · Cited by 151
Clinical landscape of macrophage-reprogramming cancer immunotherapies
Rannikko, J. H., & Hollmén, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02715-6 · Cited by 169
“Furthermore, great expectations have been placed on targeting TAMs, as they were long thought to exist in and switch between two states, tumour-promoting immunosuppressive (M2-like) macrophages and anti-tumoural pro-in fl amma-tory (M1-like) macrophages [6, 7].”
Aung, A., Kumar, V., Theprungsirikul, J., Davey, S. K., & Varghese, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0342 · Cited by 146
Role of LFA-1 and ICAM-1 in Cancer
Reina, M., & Espel, E. (2017) · Cancers · doi:10.3390/cancers9110153 · Cited by 148
A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Wolfram, J., Nizzero, S., Liu, H., Li, F., Zhang, G., Li, Z., Shen, H., Blanco, E., & Mauro Ferrari, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-14221-2 · Cited by 150
Dual Role of Macrophage in Tumor Immunity
Tamura, R., Tanaka, T., Yamamoto, Y., Akasaki, Y., & Sasaki, H. (2018) · Immunotherapy · doi:10.2217/imt-2018-0006 · Cited by 148
Molecular Mechanisms of Cancer-Induced Sleep Disruption
Walker, W. H., II, & Borniger, J. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112780 · Cited by 149
Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment
Xie, Q., Ding, J. P., & Chen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.027 · Cited by 155
Kim, H.-Y., Li, R., Ng, T. S. C., Courties, G., Rodell, C. B., Prytyskach, M., Köhler, R. H., Pittet, M. J., Nahrendorf, M., Weissleder, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b04338 · Cited by 145
Chen, B., Gao, A., Tu, B., Wang, Y., Yu, X., Wang, Y., Xiu, Y., Wang, B., Wan, Y., & Huang, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120187 · Cited by 145
Guo, Q., Jin, Z., Yuan, Y., Liu, R., Xu, T., Wei, H., Xu, X., He, S., Chen, S., Shi, Z., et al. (2016) · Journal of Immunology Research · doi:10.1155/2016/9720912 · Cited by 144
Dammeijer, F. F., Lievense, L. A., Kaijen-Lambers, M. E. H., van Nimwegen, M., Bezemer, K., Hegmans, J. P., van Hall, T., Hendriks, R. W., & Aerts, J. G. J. V. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0309 · Cited by 144
Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies
Raggi, C., Mousa, H. S., Correnti, M., Sica, A., & Invernizzi, P. (2015) · Oncogene · doi:10.1038/onc.2015.132 · Cited by 148
Zacksenhaus, E., Shrestha, M., Liu, J. C., Vorobieva, I., Chung, P. E. D., Ju, Y., Nir, U., & Jiang, Z. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.002 · Cited by 143
Growth and Immune Evasion of Lymph Node Metastasis
Jones, D., Pereira, E. R., & Padera, T. P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00036 · Cited by 146
Myeloid cell–synthesized coagulation factor X dampens antitumor immunity
Graf, C., Wilgenbus, P., Pagel, S., Pott, J., Marini, F., Reyda, S., Kitano, M., Macher-Göppinger, S., Weiler-Guettler, H., & Ruf, W. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw8405 · Cited by 145
Valilou, S. F., Keshavarz‐Fathi, M., Silvestris, N., Argentiero, A., & Rezaei, N. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.01.007 · Cited by 147
M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942
Wei, K., Ma, Z., Yang, F., Zhao, X., Jiang, W., Pan, C., Li, Z., Pan, X., He, Z., Xu, J., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.045 · Cited by 139
Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response
Sahraei, M., Chaube, B., Liu, Y., Sun, J., Kaplan, A. R., Price, N. L., Ding, W. Y., Oyaghire, S. N., García-Milian, R., Mehta, S. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127125 · Cited by 141
Azevedo, R., Shoshan, E., Whang, S., Markel, G., Jaiswal, A. R., Liu, A. J., Curran, M. A., Travassos, L. R., & Bar‐Eli, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846915 · Cited by 138
Redefining macrophage and neutrophil biology in the metastatic cascade
Güç, E., & Pollard, J. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.022 · Cited by 150
Self-citationImmune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 147
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 140
Győri, D., Lim, E. L., Grant, F. M., Spensberger, D., Roychoudhuri, R., Shuttleworth, S. J., Okkenhaug, K., Stephens, L., & Hawkins, P. T. (2018) · JCI Insight · doi:10.1172/jci.insight.120631 · Cited by 141
Metadata
- Authors
- Noy, R., & Pollard, J. W.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Pollard, Jeffrey W.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 41
- Issue
- 1
- Pages
- 49-61
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC4137410
- OpenAlex
- W1971620413
- Cited by
- 4,089
- References
- 136
- Citations by year
- 2026: 258 · 2025: 326 · 2024: 359 · 2023: 393 · 2022: 485 · 2021: 479 · 2020: 424 · 2019: 379 · 2018: 297 · 2017: 285 · 2016: 215 · 2015: 157 · 2014: 27
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-11-20)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust (101067, 101067/Z/13/Z)
- National Institutes of Health (UL1TR001073)
- National Cancer Institute (P01CA100324, R01CA172451)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-associated macrophages, tumor microenvironment, tumor angiogenesis, tumor invasion, metastasis, pre-metastatic niche, immunosuppression, natural killer cells, T cells, macrophage-targeted therapy, combination cancer therapy
- MeSH terms
- Animals, Cell Movement, Cell Survival, Cell Transformation, Neoplastic, Humans, Immunosuppression Therapy, Macrophages, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Cell Lineage, Cell Proliferation, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
